The latest price target for Design Therapeutics (NASDAQ:DSGN) was reported by Leerink Partners on December 3, 2025. The analyst firm set a price target for $14.00 expecting DSGN to rise to within 12 months (a possible 50.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Design Therapeutics (NASDAQ:DSGN) was provided by Leerink Partners, and Design Therapeutics upgraded their outperform rating.

The last upgrade for Design Therapeutics Inc happened on December 3, 2025 when Leerink Partners raised their price target to $14. Leerink Partners previously had a market perform for Design Therapeutics Inc.

The last downgrade for Design Therapeutics Inc happened on August 15, 2023 when Wedbush changed their price target from N/A to $6 for Design Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on December 3, 2025 so you should expect the next rating to be made available sometime around December 3, 2026.

While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a upgraded with a price target of $7.00 to $14.00. The current price Design Therapeutics (DSGN) is trading at is $9.28, which is within the analyst’s predicted range.